

**PPP3CB Antibody (N-term)**  
**Purified Rabbit Polyclonal Antibody (Pab)**  
**Catalog # AP8464a****Specification**

---

**PPP3CB Antibody (N-term) - Product Information**

Application	IHC-P, WB,E
Primary Accession	<a href="#">P16298</a>
Other Accession	<a href="#">P20651</a> , <a href="#">P48453</a>
Reactivity	Human
Predicted	Mouse, Rat
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Calculated MW	59024
Antigen Region	1-30

**PPP3CB Antibody (N-term) - Additional Information****Gene ID** 5532**Other Names**

Serine/threonine-protein phosphatase 2B catalytic subunit beta isoform, CAM-PRP catalytic subunit, Calmodulin-dependent calcineurin A subunit beta isoform, PPP3CB, CALNA2, CALNB, CNA2

**Target/Specificity**

This PPP3CB antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1-30 amino acids from the N-terminal region of human PPP3CB.

**Dilution**

IHC-P~~1:50~100

WB~~1:1000

E~~Use at an assay dependent concentration.

**Format**

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

**Storage**

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

**Precautions**

PPP3CB Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.

**PPP3CB Antibody (N-term) - Protein Information**

**Name** PPP3CB

**Synonyms** CALNA2, CALNB, CNA2

**Function** Calcium-dependent, calmodulin-stimulated protein phosphatase which plays an essential role in the transduction of intracellular  $\text{Ca}^{2+}$ -mediated signals (PubMed:[19154138](#), PubMed:[25720963](#), PubMed:[26794871](#), PubMed:[32753672](#)). Dephosphorylates TFEB in response to lysosomal  $\text{Ca}^{2+}$  release, resulting in TFEB nuclear translocation and stimulation of lysosomal biogenesis (PubMed:[25720963](#), PubMed:[32753672](#)). Dephosphorylates and activates transcription factor NFATC1 (PubMed:[19154138](#)). Dephosphorylates and inactivates transcription factor ELK1 (PubMed:[19154138](#)). Dephosphorylates DARPP32 (PubMed:[19154138](#)). Negatively regulates MAP3K14/NIK signaling via inhibition of nuclear translocation of the transcription factors RELA and RELB (By similarity). May play a role in skeletal muscle fiber type specification (By similarity).

**Cellular Location**


Cytoplasm.

**PPP3CB Antibody (N-term) - Protocols**


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


**PPP3CB Antibody (N-term) - Images**



Western blot analysis of anti-PPP3CB Pab (Cat. #AP8464a) in mouse kidney tissue lysate. PPP3CB(arrow) was detected using the purified Pab.



Western blot analysis of anti-PPP3CB Antibody (N-term) (Cat.#AP8464a) in Jurkat cell line lysates (35ug/lane). PPP3CB(arrow) was detected using the purified Pab.



Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.

#### **PPP3CB Antibody (N-term) - Background**

PPP3CB is a calcium-dependent, calmodulin-stimulated protein phosphatase. This subunit may have a role in the calmodulin activation of calcineurin.

#### **PPP3CB Antibody (N-term) - References**

- Katanosaka, Y., et al., J. Biol. Chem. 280(7):5764-5772 (2005).
- Bell, O., et al., Mol. Endocrinol. 19(2):516-526 (2005).
- Bennasser, Y., et al., Virology 303(1):174-180 (2002).
- Kissinger, C.R., et al., Nature 378(6557):641-644 (1995).
- Muramatsu, T., et al., Biochim. Biophys. Acta 1178(1):117-120 (1993).